SOLID BIOSCIENCES INC

SLDBNASDAQ

🏆 #2715 by market capEarnings Nov 2US Equity

$7.17▼ $0.13 (−1.78%)

Market closed · at close

🔔

Track SLDB

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 1.8%

7d▼ 10.4%

14d▼ 17.8%

30d▼ 25.1%

ytd▲ 26.7%

1y▲ 16.0%

🏦Market Cap

$706M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $7.06 – $7.26
52-Week Range: $3.79 – $11.45
Volume: $2.15B
Avg Volume: $1.61B
Shares Outstanding: 98.4M
Next Earnings: Nov 9, 2026

Fundamentals Snapshot

Annual Revenue: $55M
Last Q Revenue: $13M
P/E Ratio: -3.8
P/S Ratio: 0.0x
EPS (TTM): $-1.44
Dividend Yield: 0.00%
Dilution (1yr): +76.8%

Why Investors Own SLDB

✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SOLID BIOSCIENCES INC

SLDB

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$179M▲ +38.1% YoY

Free Cash Flow

−$157M▲ +56.4% YoY

Shares Outstanding

94.7M▲ +76.8% YoY

Net Cash

$39M▼ −$17M YoY

StockOtter · stockotter.space

About SOLID BIOSCIENCES INC

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

🦦